Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Completed

Conditions studied: Metastatic Hormone Refractory Prostate Cancer

In brief

The purpose of this study is to look at the genetic changes that RAD001 causes in prostate cancer cells and how those changes relate to patients' response to RAD001 treatment.

Key facts

Study ID

NCT00636090

Run by

Duke University

People needed

35

Starts

2007-01-01

Expected to finish

2010-01-01

Last updated by the study team

2013-12-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be enrolled in the clinical study entitled: A Single Arm, Phase II Study of RAD001 in Patients with Metastatic, Hormone-Refractory Prostate Cancer at the time of enrollment onto this study.

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.